Monte Rosa Therapeutics, Inc. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax
Monte Rosa Therapeutics, Inc. (GLUE) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax of $756.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2025 was $756.00K.
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2024 was -$1.04M.
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2023 was -$1.61M, a 308.53% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, before tax for fiscal 2022 was $774.00K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 12 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax 12 month as first filed |
|---|---|---|
| 2025-12-31 | $756.00K 10-K · filed 2026-03-17 | |
| 2024-12-31 | -$1.04M 10-K · filed 2026-03-17 | $80.00K 10-K · filed 2025-03-20 |
| 2023-12-31 | -$1.61M 10-K · filed 2025-03-20 | |
| 2022-12-31 | $774.00K 10-K · filed 2024-03-14 | |
| 2021-12-31 | -$1.29M 10-K · filed 2023-03-16 | $1.29M 10-K · filed 2022-03-29 |
| 2020-12-31 | $1.06M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |